 Aimmune Therapeutics NASDAQ:AIMT was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report released on Friday, Zacks.com reports. According to Zacks, Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Companys characterized oral desensitization ... 